There are currently 181 clinical trials in Clearwater, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Morton Plant Hospital, GSK Investigational Site, Clinical Research of West Florida, Inc and Clinical Research of West Florida. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype
Recruiting
This study will assess whether switching participants who have benefitted from mepolizumab or benralizumab to GSK3511294 (Depemokimab) is non-inferior to maintaining current treatment on the annualized rate of clinically significant exacerbations in participants with severe asthma with an eosinophilic phenotype. Throughout the study, all participants will continue their non-biologic Baseline standard of care (SoC) asthma treatment.
Gender:
All
Ages:
12 years and above
Trial Updated:
11/06/2023
Locations: GSK Investigational Site, Clearwater, Florida
Conditions: Asthma
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
Recruiting
TARGET-IBD is a 5-year, longitudinal, observational study of adult and pediatric patients (age 2 and above) being managed for Inflammatory Bowel Disease (IBD) in usual clinical practice. TARGET-IBD will create a research registry of patients with IBD within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Gender:
All
Ages:
2 years and above
Trial Updated:
10/27/2023
Locations: Gastro Florida, Clearwater, Florida
Conditions: Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
Recruiting
This is a multi-part, randomized, double-blind, placebo-controlled Phase 2 clinical study comparing the safety and efficacy of bezuclastinib (CGT9486) plus best supportive care (BSC) with placebo plus BSC in patients with nonadvanced systemic mastocytosis (NonAdvSM), including indolent systemic mastocytosis and smoldering systemic mastocytosis, whose symptoms are not adequately controlled by BSC. This study will be conducted in three parts. Patients in Parts 1a, 1b and 2 will receive bezuclastin... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/27/2023
Locations: Innovative Research of West Florida, Clearwater, Florida
Conditions: SSM, Mastocytosis, Indolent, Mastocytosis, Systemic, Mastocytosis
Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial
Recruiting
The objective of the PORTICO pivotal IDE trial is to evaluate the safety and effectiveness of the St Jude Medical (SJM) Portico Transcatheter Heart Valve and Delivery Systems (Portico) in the treatment of severe symptomatic aortic stenosis via transfemoral and alternative delivery methods in high risk and extreme risk patients.
Gender:
All
Ages:
21 years and above
Trial Updated:
10/24/2023
Locations: Morton Plant Valve Clinic, Clearwater, Florida
Conditions: Aortic Valve Stenosis
Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
Recruiting
The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
10/17/2023
Locations: Clinical Research of West Florida, Inc., Clearwater, Florida
Conditions: Gout, Hyperuricemia, Gout Flare, Tophi
VK2735 for Weight Management Phase 2
Recruiting
This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition. VK2735 or matched placebo will be administered once weekly.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/28/2023
Locations: Viking Clinical Site #116, Clearwater, Florida +1 locations
Conditions: Weight Loss
Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia
Recruiting
A open label multi-center 3-period multidose, PK/PD and drug-drug interaction (DDI) study to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of 7 days of treatment with two doses of dotinurad monotherapy, and to evaluate the effect of dotinurad, as monotherapy and in combination with allopurinol, versus allopurinol monotherapy, on the PK of each, and to assess the additive PD effects on serum uric acid and urinary urate excretion in U.S. patients with gout and hyperuricemia
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
09/20/2023
Locations: Clinical Research of West Florida, Clearwater, Florida
Conditions: Gout, Hyperuricemia
Safety and Efficacy of TU-100 as an Adjunct to an Enhanced Recovery After Surgery in Subjects Undergoing Bowel Resection
Recruiting
This multicenter, randomized, double-blinded, placebo-controlled study will evaluate the effect of TU-100 on resolution of postoperative ileus (POI) in subjects undergoing open or laparoscopic bowel resection (BR).
Gender:
All
Ages:
18 years and above
Trial Updated:
09/14/2023
Locations: Clearwater Site, Clearwater, Florida
Conditions: Enhanced Recovery After Surgery
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
Recruiting
This is an open-label, multi-center, Phase 3 study to evaluate tapinarof cream, 1% in pediatric subjects with plaque psoriasis.
Gender:
All
Ages:
Between 2 years and 17 years
Trial Updated:
09/07/2023
Locations: Dermavant Clinical Site, Clearwater, Florida
Conditions: Plaque Psoriasis
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)
Recruiting
The purpose of this study is to evaluate the efficacy and the safety of two doses of CHF6001 (Tanimilast) as add-on to maintenance triple therapy in the target patient population.
Gender:
All
Ages:
40 years and above
Trial Updated:
08/31/2023
Locations: Chiesi Clinical Trial - Site 840652, Clearwater, Florida +1 locations
Conditions: Chronic Obstructive Pulmonary Disease
Personalized Therapy Study - HFRS (TriageHF) Post Approval Study
Recruiting
Medtronic is sponsoring the HFRS PAS to evaluate the HFRS feature (TriageHF) when used in routine clinical practice following commercial release. The HFRS PAS is conducted within Medtronic's Product Surveillance Registry (PSR) platform.
Gender:
All
Ages:
All
Trial Updated:
08/29/2023
Locations: Clearwater Cardiovascular Consultants, Clearwater, Florida
Conditions: Heart Failure
Personalized Therapy Study - Intrinsic Antitachycardia Pacing Post-Approval Study (iATP PAS)
Recruiting
Medtronic is sponsoring the Intrinsic Antitachycardia Pacing Post-Approval Study (iATP PAS) to further confirm safety and effectiveness of ventricular iATP therapy in routine clinical practice, following commercial release of iATP-capable devices. The iATP PAS is conducted within Medtronic's Product Surveillance Registry platform (NCT01524276).
Gender:
All
Ages:
All
Trial Updated:
08/29/2023
Locations: Clearwater Cardiovascular Consultants, Clearwater, Florida
Conditions: Ventricular Tachycardia